AAAAAA
Results: 126-150/688
Authors:
TANAKA O
KONDO T
OTANI K
YASUI N
TOKINAGA N
KANEKO S
Citation: O. Tanaka et al., SINGLE ORAL DOSE KINETICS OF ZOTEPINE AND ITS RELATIONSHIP TO PROLACTIN RESPONSE AND SIDE-EFFECTS, Therapeutic drug monitoring, 20(1), 1998, pp. 117-119
Authors:
JALAVA KM
PARTANEN J
NEUVONEN PJ
Citation: Km. Jalava et al., ITRACONAZOLE DECREASES RENAL CLEARANCE OF DIGOXIN, Therapeutic drug monitoring, 19(6), 1997, pp. 609-613
Authors:
ANDRES I
LOPEZ R
POU L
PINOL F
PASCUAL C
Citation: I. Andres et al., VANCOMYCIN MONITORING - ONE OR 2 SERUM LEVELS, Therapeutic drug monitoring, 19(6), 1997, pp. 614-619
Authors:
BATTINO D
CROCI D
GRANATA T
ESTIENNE M
PISANI F
AVANZINI G
Citation: D. Battino et al., LAMOTRIGINE PLASMA-CONCENTRATIONS IN CHILDREN AND ADULTS - INFLUENCE OF AGE AND ASSOCIATED THERAPY, Therapeutic drug monitoring, 19(6), 1997, pp. 620-627
Authors:
BRAUN F
SCHUTZ E
CHRISTIANS U
LORF T
SCHIFFMANN JH
ARMSTRONG VW
SCHROTER W
SEWING KF
OELLERICH M
RINGE B
Citation: F. Braun et al., PITFALLS IN MONITORING TACROLIMUS (FK-506), Therapeutic drug monitoring, 19(6), 1997, pp. 628-631
Authors:
ELYAZIGI A
BERRY J
EZZAT A
WAHAB FA
Citation: A. Elyazigi et al., EFFECT OF TAMOXIFEN ON THE PHARMACOKINETICS OF DOXORUBICIN IN PATIENTS WITH NON-HODGKINS-LYMPHOMA, Therapeutic drug monitoring, 19(6), 1997, pp. 632-636
Authors:
GORODISCHER R
BURTIN P
VERJEE Z
HWANG P
KOREN G
Citation: R. Gorodischer et al., IS SALIVA SUITABLE FOR THERAPEUTIC MONITORING OF ANTICONVULSANTS IN CHILDREN - AN EVALUATION IN THE ROUTINE CLINICAL SETTING, Therapeutic drug monitoring, 19(6), 1997, pp. 637-642
URINARY-EXCRETION OF CODEINE, ETHYLMORPHINE, AND THEIR METABOLITES - RELATION TO THE CYP2D6 ACTIVITY
Authors:
HEDENMALM K
SUNDGREN M
GRANBERG K
SPIGSET O
DAHLQVIST R
Citation: K. Hedenmalm et al., URINARY-EXCRETION OF CODEINE, ETHYLMORPHINE, AND THEIR METABOLITES - RELATION TO THE CYP2D6 ACTIVITY, Therapeutic drug monitoring, 19(6), 1997, pp. 643-649
Authors:
JONES TE
MORRIS RG
Citation: Te. Jones et Rg. Morris, SURVEY OF CYCLOSPORINE THERAPEUTIC RANGES, ASSAY METHODOLOGY, AND USEOF SPARING AGENTS IN AUSTRALASIAN TRANSPLANT CENTERS, Therapeutic drug monitoring, 19(6), 1997, pp. 650-656
Authors:
OKAZAKI M
TANIGAWARA Y
KITA T
KOMADA F
OKUMURA K
Citation: M. Okazaki et al., CROSS-REACTIVITY OF TDX AND OPUS IMMUNOASSAY SYSTEMS FOR SERUM DIGOXIN DETERMINATION, Therapeutic drug monitoring, 19(6), 1997, pp. 657-662
Authors:
GIVERHAUG T
BERGAN S
LOENNECHEN T
RUGSTAD HE
AARBAKKE J
Citation: T. Giverhaug et al., ANALYSIS OF METHYLATED 6-MERCAPTOPURINE METABOLITES IN HUMAN RED-BLOOD-CELLS - COMPARISON OF 2 METHODS, Therapeutic drug monitoring, 19(6), 1997, pp. 663-668
Authors:
LEGUELLEC C
GAUDET ML
LAMANETRE S
BRETEAU M
Citation: C. Leguellec et al., STABILITY OF RIFAMPIN IN PLASMA - CONSEQUENCES FOR THERAPEUTIC MONITORING AND PHARMACOKINETIC STUDIES, Therapeutic drug monitoring, 19(6), 1997, pp. 669-674
Authors:
LIN CC
VEALS J
KORDUBA C
HILBERT MJ
NOMEIR A
Citation: Cc. Lin et al., ANALYSIS OF ISEPAMICIN IN HUMAN PLASMA BY RADIOIMMUNOASSAY, MICROBIOLOGIC ASSAY, AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY, Therapeutic drug monitoring, 19(6), 1997, pp. 675-681
Authors:
ONYEJI CO
AIDELOJE SO
Citation: Co. Onyeji et So. Aideloje, ION-PAIR REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ANALYSIS OF HALOFANTRINE AND DESBUTYLHALOFANTRINE IN HUMAN PLASMA, Therapeutic drug monitoring, 19(6), 1997, pp. 682-687
Authors:
SALLUSTIO BC
MORRIS RG
Citation: Bc. Sallustio et Rg. Morris, HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY QUANTITATION OF PLASMA LAMOTRIGINE CONCENTRATIONS - APPLICATION MEASURING TROUGH CONCENTRATIONS IN PATIENTS WITH EPILEPSY, Therapeutic drug monitoring, 19(6), 1997, pp. 688-693
Authors:
SALM P
TAYLOR PJ
CLARK A
BALDERSON GA
GRYGOTIS A
NORRIS RLG
LYNCH SV
SHAW LM
POND SM
Citation: P. Salm et al., HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY TANDEM MASS-SPECTROMETRY AS A REFERENCE FOR ANALYSIS OF TACROLIMUS TO ASSESS 2 IMMUNOASSAYS IN PATIENTS WITH LIVER AND RENAL-TRANSPLANTS, Therapeutic drug monitoring, 19(6), 1997, pp. 694-700
Authors:
BOULIEU R
BASTIEN O
GAILLARD S
FLAMENS C
Citation: R. Boulieu et al., PHARMACOKINETICS OF ACYCLOVIR IN PATIENTS UNDERGOING CONTINUOUS VENOVENOUS HEMODIALYSIS, Therapeutic drug monitoring, 19(6), 1997, pp. 701-704
Authors:
LANCHOTE VL
PING WC
SANTOS SRCJ
Citation: Vl. Lanchote et al., DETERMINATION OF ANTIPYRINE AND METABOLITES IN PLASMA OF A PATIENT WITH MILD RENAL-FAILURE, Therapeutic drug monitoring, 19(6), 1997, pp. 705-710
Authors:
GUPTA A
JOSHI P
JORTANI SA
VALDES R
THORKELSSON T
VERJEE Z
SHEMIE S
Citation: A. Gupta et al., A CASE OF NONDIGITALIS CARDIAC GLYCOSIDE TOXICITY, Therapeutic drug monitoring, 19(6), 1997, pp. 711-714
Authors:
ARMIJO JA
CUADRADO A
BRAVO J
ARTEAGA R
Citation: Ja. Armijo et al., VIGABATRIN SERUM CONCENTRATION TO DOSAGE RATIO - INFLUENCE OF AGE ANDASSOCIATED ANTIEPILEPTIC DRUGS, Therapeutic drug monitoring, 19(5), 1997, pp. 491-498
Authors:
ERIKSSON AS
BOREUS LO
Citation: As. Eriksson et Lo. Boreus, NO INCREASE IN CARBAMAZEPINE-10,11-EPOXIDE DURING ADDITION OF LAMOTRIGINE TREATMENT IN CHILDREN, Therapeutic drug monitoring, 19(5), 1997, pp. 499-501
Authors:
BERGAN S
BENTDAL O
SODAL G
BRUN A
RUGSTAD HE
STOKKE O
Citation: S. Bergan et al., PATTERNS OF AZATHIOPRINE METABOLITES IN NEUTROPHILS, LYMPHOCYTES, RETICULOCYTES, AND ERYTHROCYTES - RELEVANCE TO TOXICITY AND MONITORING INRECIPIENTS OF RENAL-ALLOGRAFTS, Therapeutic drug monitoring, 19(5), 1997, pp. 502-509
Authors:
CASPI O
ZYLBERKATZ E
GOTSMAN O
WOLF DG
CARACO Y
Citation: O. Caspi et al., DIGOXIN INTOXICATION IN A PATIENT WITH END-STAGE RENAL-DISEASE - EFFICACY OF DIGOXIN-SPECIFIC FAB ANTIBODY FRAGMENTS AND PERITONEAL-DIALYSIS, Therapeutic drug monitoring, 19(5), 1997, pp. 510-515
Authors:
ISSY AM
LANCHOTE VL
DECARVALHO D
SILVA HC
Citation: Am. Issy et al., LACK OF KINETIC INTERACTION BETWEEN VALPROIC ACID AND CITRUS PECTIN, Therapeutic drug monitoring, 19(5), 1997, pp. 516-520
Authors:
BIEDERBICK W
JOSEPH G
RUMP A
THEISOHN M
KLAUS W
Citation: W. Biederbick et al., CAFFEINE IN SALIVA AFTER PERORAL INTAKE - EARLY SAMPLE COLLECTION AS A POSSIBLE SOURCE OF ERROR, Therapeutic drug monitoring, 19(5), 1997, pp. 521-524